APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD45 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CD45 Antibody Market Analysis and Forecast 2026-2032

19 December 2025208 pages

Choose your research edition.

Industry ResearchCD45 Antibody Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal CD45 Antibody Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal CD45 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD45 Antibody Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal CD45 Antibody Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global CD45 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD45 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CD45 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CD45 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CD45 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CD45 Antibody include Abcam, BD Biosciences, Beckman Coulter, BioLegend, Bio-Rad, Bioss, Cell Signaling Technology, Creative Biolabs and Creative Diagnostics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD45 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CD45 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for CD45 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD45 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CD45 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CD45 Antibody revenue, projected growth trends, production technology, application and end-user industry.

CD45 Antibody Segment by Company

Abcam

BD Biosciences

Beckman Coulter

BioLegend

Bio-Rad

Bioss

Cell Signaling Technology

Creative Biolabs

Creative Diagnostics

FabGennix

HUABIO

Leinco Technologies

LSBio

Miltenyi Biotec

NSJ Bioreagents

United States Biological

Boster Biological Technology

Merck

Thermo Fisher Scientific

CD45 Antibody Segment by Type

Polyclonal

Monoclonal

CD45 Antibody Segment by Application

Western Blot

Immunocytochemistry

Immunofluorescence

Immunohistochemistry

Others

CD45 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD45 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD45 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD45 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CD45 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CD45 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD45 Antibody revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CD45 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polyclonal Major Player Table 3. Monoclonal Major Player Table 4. Global CD45 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Western Blot Major Player Table 6. Immunocytochemistry Major Player Table 7. Immunofluorescence Major Player Table 8. Immunohistochemistry Major Player Table 9. Others Major Player Table 10. CD45 Antibody Industry Trends Table 11. CD45 Antibody Industry Drivers Table 12. CD45 Antibody Industry Opportunities and Challenges Table 13. CD45 Antibody Industry Restraints Table 14. Global CD45 Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global CD45 Antibody Market Size by Region (2021-2026) & (US$ Million) Table 16. Global CD45 Antibody Market Share by Region (2021-2026) Table 17. Global CD45 Antibody Market Size by Region (2027-2032) & (US$ Million) Table 18. Global CD45 Antibody Market Share by Region (2027-2032) Table 19. Global CD45 Antibody Revenue by Players (US$ Million) & (2021-2026) Table 20. Global CD45 Antibody Revenue Market Share by Players (2021-2026) Table 21. Global CD45 Antibody Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global CD45 Antibody Key Players Headquarters & Area Served Table 23. Global CD45 Antibody Players, Product Type & Application Table 24. Global CD45 Antibody Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global CD45 Antibody by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global CD45 Antibody Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 29. Global CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 30. Global CD45 Antibody Revenue Market Share by Type (2021-2026) Table 31. Global CD45 Antibody Revenue Market Share by Type (2027-2032) Table 32. Global CD45 Antibody Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 34. Global CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 35. Global CD45 Antibody Revenue Market Share by Application (2021-2026) Table 36. Global CD45 Antibody Revenue Market Share by Application (2027-2032) Table 37. Abcam Company Information Table 38. Abcam Business Overview Table 39. Abcam CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Abcam CD45 Antibody Product Portfolio Table 41. Abcam Recent Development Table 42. BD Biosciences Company Information Table 43. BD Biosciences Business Overview Table 44. BD Biosciences CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. BD Biosciences CD45 Antibody Product Portfolio Table 46. BD Biosciences Recent Development Table 47. Beckman Coulter Company Information Table 48. Beckman Coulter Business Overview Table 49. Beckman Coulter CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Beckman Coulter CD45 Antibody Product Portfolio Table 51. Beckman Coulter Recent Development Table 52. BioLegend Company Information Table 53. BioLegend Business Overview Table 54. BioLegend CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. BioLegend CD45 Antibody Product Portfolio Table 56. BioLegend Recent Development Table 57. Bio-Rad Company Information Table 58. Bio-Rad Business Overview Table 59. Bio-Rad CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bio-Rad CD45 Antibody Product Portfolio Table 61. Bio-Rad Recent Development Table 62. Bioss Company Information Table 63. Bioss Business Overview Table 64. Bioss CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Bioss CD45 Antibody Product Portfolio Table 66. Bioss Recent Development Table 67. Cell Signaling Technology Company Information Table 68. Cell Signaling Technology Business Overview Table 69. Cell Signaling Technology CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Cell Signaling Technology CD45 Antibody Product Portfolio Table 71. Cell Signaling Technology Recent Development Table 72. Creative Biolabs Company Information Table 73. Creative Biolabs Business Overview Table 74. Creative Biolabs CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Creative Biolabs CD45 Antibody Product Portfolio Table 76. Creative Biolabs Recent Development Table 77. Creative Diagnostics Company Information Table 78. Creative Diagnostics Business Overview Table 79. Creative Diagnostics CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Creative Diagnostics CD45 Antibody Product Portfolio Table 81. Creative Diagnostics Recent Development Table 82. FabGennix Company Information Table 83. FabGennix Business Overview Table 84. FabGennix CD45 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. FabGennix CD45 Antibody Product Portfolio Table 86. FabGennix Recent Development Table 87. HUABIO Company Information Table 88. HUABIO Business Overview Table 89. HUABIO CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. HUABIO CD45 Antibody Product Portfolio Table 91. HUABIO Recent Development Table 92. Leinco Technologies Company Information Table 93. Leinco Technologies Business Overview Table 94. Leinco Technologies CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Leinco Technologies CD45 Antibody Product Portfolio Table 96. Leinco Technologies Recent Development Table 97. LSBio Company Information Table 98. LSBio Business Overview Table 99. LSBio CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. LSBio CD45 Antibody Product Portfolio Table 101. LSBio Recent Development Table 102. Miltenyi Biotec Company Information Table 103. Miltenyi Biotec Business Overview Table 104. Miltenyi Biotec CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Miltenyi Biotec CD45 Antibody Product Portfolio Table 106. Miltenyi Biotec Recent Development Table 107. NSJ Bioreagents Company Information Table 108. NSJ Bioreagents Business Overview Table 109. NSJ Bioreagents CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. NSJ Bioreagents CD45 Antibody Product Portfolio Table 111. NSJ Bioreagents Recent Development Table 112. United States Biological Company Information Table 113. United States Biological Business Overview Table 114. United States Biological CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. United States Biological CD45 Antibody Product Portfolio Table 116. United States Biological Recent Development Table 117. Boster Biological Technology Company Information Table 118. Boster Biological Technology Business Overview Table 119. Boster Biological Technology CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Boster Biological Technology CD45 Antibody Product Portfolio Table 121. Boster Biological Technology Recent Development Table 122. Merck Company Information Table 123. Merck Business Overview Table 124. Merck CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Merck CD45 Antibody Product Portfolio Table 126. Merck Recent Development Table 127. Thermo Fisher Scientific Company Information Table 128. Thermo Fisher Scientific Business Overview Table 129. Thermo Fisher Scientific CD45 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Thermo Fisher Scientific CD45 Antibody Product Portfolio Table 131. Thermo Fisher Scientific Recent Development Table 132. North America CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 133. North America CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 134. North America CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 135. North America CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 136. North America CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America CD45 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 138. North America CD45 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 139. Europe CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe CD45 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 145. Europe CD45 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 146. China CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 147. China CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 148. China CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 149. China CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia CD45 Antibody Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia CD45 Antibody Revenue by Region (US$ Million) & (2021-2026) Table 156. Asia CD45 Antibody Revenue by Region (US$ Million) & (2027-2032) Table 157. SAMEA CD45 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 158. SAMEA CD45 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 159. SAMEA CD45 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA CD45 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. SAMEA CD45 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 163. SAMEA CD45 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. CD45 Antibody Image Figure 2. Global CD45 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD45 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polyclonal Image Figure 5. Monoclonal Image Figure 6. Global CD45 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CD45 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 8. Western Blot Image Figure 9. Immunocytochemistry Image Figure 10. Immunofluorescence Image Figure 11. Immunohistochemistry Image Figure 12. Others Image Figure 13. Global CD45 Antibody Market Size (US$ Million) & (2021-2032) Figure 14. Global CD45 Antibody Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global CD45 Antibody Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global CD45 Antibody Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global CD45 Antibody Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CD45 Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global CD45 Antibody Revenue Market Share by Type (2021-2032) Figure 21. Global CD45 Antibody Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global CD45 Antibody Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global CD45 Antibody Revenue Market Share by Application (2021-2032) Figure 24. North America CD45 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America CD45 Antibody Revenue Share by Type (2021-2032) Figure 26. North America CD45 Antibody Revenue Share by Application (2021-2032) Figure 27. North America CD45 Antibody Revenue Share by Country (2021-2032) Figure 28. United States CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe CD45 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe CD45 Antibody Revenue Share by Type (2021-2032) Figure 33. Europe CD45 Antibody Revenue Share by Application (2021-2032) Figure 34. Europe CD45 Antibody Revenue Share by Country (2021-2032) Figure 35. Germany CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China CD45 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China CD45 Antibody Revenue Share by Type (2021-2032) Figure 45. China CD45 Antibody Revenue Share by Application (2021-2032) Figure 46. Asia CD45 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia CD45 Antibody Revenue Share by Type (2021-2032) Figure 48. Asia CD45 Antibody Revenue Share by Application (2021-2032) Figure 49. Asia CD45 Antibody Revenue Share by Region (2021-2032) Figure 50. Japan CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA CD45 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA CD45 Antibody Revenue Share by Type (2021-2032) Figure 58. SAMEA CD45 Antibody Revenue Share by Application (2021-2032) Figure 59. SAMEA CD45 Antibody Revenue Share by Country (2021-2032) Figure 60. Brazil CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt CD45 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Immunocytochemistry
  • Immunofluorescence
  • Immunohistochemistry
  • Others
Companies covered
  • Abcam
  • BD Biosciences
  • Beckman Coulter
  • BioLegend
  • Bio-Rad
  • Bioss
  • Cell Signaling Technology
  • Creative Biolabs
  • Creative Diagnostics
  • FabGennix
  • HUABIO
  • Leinco Technologies
  • LSBio
  • Miltenyi Biotec
  • NSJ Bioreagents
  • United States Biological
  • Boster Biological Technology
  • Merck
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CD45 Antibody Market by Type
  3. 1.2.1 Global CD45 Antibody Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polyclonal
  5. 1.2.3 Monoclonal
  6. 1.3 CD45 Antibody Market by Application
  7. 1.3.1 Global CD45 Antibody Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Western Blot
  9. 1.3.3 Immunocytochemistry
  10. 1.3.4 Immunofluorescence
  11. 1.3.5 Immunohistochemistry
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 CD45 Antibody Market Dynamics
  1. 2.1 CD45 Antibody Industry Trends
  2. 2.2 CD45 Antibody Industry Drivers
  3. 2.3 CD45 Antibody Industry Opportunities and Challenges
  4. 2.4 CD45 Antibody Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CD45 Antibody Market Perspective (2021-2032)
  2. 3.2 Global CD45 Antibody Growth Trends by Region
  3. 3.2.1 Global CD45 Antibody Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CD45 Antibody Market Size by Region (2021-2026)
  5. 3.2.3 Global CD45 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CD45 Antibody Revenue by Players
  2. 4.1.1 Global CD45 Antibody Revenue by Players (2021-2026)
  3. 4.1.2 Global CD45 Antibody Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CD45 Antibody Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CD45 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CD45 Antibody Key Players Headquarters & Area Served
  7. 4.4 Global CD45 Antibody Players, Product Type & Application
  8. 4.5 Global CD45 Antibody Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CD45 Antibody Market CR5 and HHI
  11. 4.6.3 2025 CD45 Antibody Tier 1, Tier 2, and Tier 3
5 CD45 Antibody Market Size by Type
  1. 5.1 Global CD45 Antibody Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CD45 Antibody Revenue by Type (2021-2032)
  3. 5.3 Global CD45 Antibody Revenue Market Share by Type (2021-2032)
6 CD45 Antibody Market Size by Application
  1. 6.1 Global CD45 Antibody Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CD45 Antibody Revenue by Application (2021-2032)
  3. 6.3 Global CD45 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abcam
  2. 7.1.1 Abcam Company Information
  3. 7.1.2 Abcam Business Overview
  4. 7.1.3 Abcam CD45 Antibody Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abcam CD45 Antibody Product Portfolio
  6. 7.1.5 Abcam Recent Developments
  7. 7.2 BD Biosciences
  8. 7.2.1 BD Biosciences Company Information
  9. 7.2.2 BD Biosciences Business Overview
  10. 7.2.3 BD Biosciences CD45 Antibody Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BD Biosciences CD45 Antibody Product Portfolio
  12. 7.2.5 BD Biosciences Recent Developments
  13. 7.3 Beckman Coulter
  14. 7.3.1 Beckman Coulter Company Information
  15. 7.3.2 Beckman Coulter Business Overview
  16. 7.3.3 Beckman Coulter CD45 Antibody Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Beckman Coulter CD45 Antibody Product Portfolio
  18. 7.3.5 Beckman Coulter Recent Developments
  19. 7.4 BioLegend
  20. 7.4.1 BioLegend Company Information
  21. 7.4.2 BioLegend Business Overview
  22. 7.4.3 BioLegend CD45 Antibody Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BioLegend CD45 Antibody Product Portfolio
  24. 7.4.5 BioLegend Recent Developments
  25. 7.5 Bio-Rad
  26. 7.5.1 Bio-Rad Company Information
  27. 7.5.2 Bio-Rad Business Overview
  28. 7.5.3 Bio-Rad CD45 Antibody Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bio-Rad CD45 Antibody Product Portfolio
  30. 7.5.5 Bio-Rad Recent Developments
  31. 7.6 Bioss
  32. 7.6.1 Bioss Company Information
  33. 7.6.2 Bioss Business Overview
  34. 7.6.3 Bioss CD45 Antibody Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bioss CD45 Antibody Product Portfolio
  36. 7.6.5 Bioss Recent Developments
  37. 7.7 Cell Signaling Technology
  38. 7.7.1 Cell Signaling Technology Company Information
  39. 7.7.2 Cell Signaling Technology Business Overview
  40. 7.7.3 Cell Signaling Technology CD45 Antibody Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cell Signaling Technology CD45 Antibody Product Portfolio
  42. 7.7.5 Cell Signaling Technology Recent Developments
  43. 7.8 Creative Biolabs
  44. 7.8.1 Creative Biolabs Company Information
  45. 7.8.2 Creative Biolabs Business Overview
  46. 7.8.3 Creative Biolabs CD45 Antibody Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Creative Biolabs CD45 Antibody Product Portfolio
  48. 7.8.5 Creative Biolabs Recent Developments
  49. 7.9 Creative Diagnostics
  50. 7.9.1 Creative Diagnostics Company Information
  51. 7.9.2 Creative Diagnostics Business Overview
  52. 7.9.3 Creative Diagnostics CD45 Antibody Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Creative Diagnostics CD45 Antibody Product Portfolio
  54. 7.9.5 Creative Diagnostics Recent Developments
  55. 7.10 FabGennix
  56. 7.10.1 FabGennix Company Information
  57. 7.10.2 FabGennix Business Overview
  58. 7.10.3 FabGennix CD45 Antibody Revenue and Gross Margin (2021-2026)
  59. 7.10.4 FabGennix CD45 Antibody Product Portfolio
  60. 7.10.5 FabGennix Recent Developments
  61. 7.11 HUABIO
  62. 7.11.1 HUABIO Company Information
  63. 7.11.2 HUABIO Business Overview
  64. 7.11.3 HUABIO CD45 Antibody Revenue and Gross Margin (2021-2026)
  65. 7.11.4 HUABIO CD45 Antibody Product Portfolio
  66. 7.11.5 HUABIO Recent Developments
  67. 7.12 Leinco Technologies
  68. 7.12.1 Leinco Technologies Company Information
  69. 7.12.2 Leinco Technologies Business Overview
  70. 7.12.3 Leinco Technologies CD45 Antibody Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Leinco Technologies CD45 Antibody Product Portfolio
  72. 7.12.5 Leinco Technologies Recent Developments
  73. 7.13 LSBio
  74. 7.13.1 LSBio Company Information
  75. 7.13.2 LSBio Business Overview
  76. 7.13.3 LSBio CD45 Antibody Revenue and Gross Margin (2021-2026)
  77. 7.13.4 LSBio CD45 Antibody Product Portfolio
  78. 7.13.5 LSBio Recent Developments
  79. 7.14 Miltenyi Biotec
  80. 7.14.1 Miltenyi Biotec Company Information
  81. 7.14.2 Miltenyi Biotec Business Overview
  82. 7.14.3 Miltenyi Biotec CD45 Antibody Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Miltenyi Biotec CD45 Antibody Product Portfolio
  84. 7.14.5 Miltenyi Biotec Recent Developments
  85. 7.15 NSJ Bioreagents
  86. 7.15.1 NSJ Bioreagents Company Information
  87. 7.15.2 NSJ Bioreagents Business Overview
  88. 7.15.3 NSJ Bioreagents CD45 Antibody Revenue and Gross Margin (2021-2026)
  89. 7.15.4 NSJ Bioreagents CD45 Antibody Product Portfolio
  90. 7.15.5 NSJ Bioreagents Recent Developments
  91. 7.16 United States Biological
  92. 7.16.1 United States Biological Company Information
  93. 7.16.2 United States Biological Business Overview
  94. 7.16.3 United States Biological CD45 Antibody Revenue and Gross Margin (2021-2026)
  95. 7.16.4 United States Biological CD45 Antibody Product Portfolio
  96. 7.16.5 United States Biological Recent Developments
  97. 7.17 Boster Biological Technology
  98. 7.17.1 Boster Biological Technology Company Information
  99. 7.17.2 Boster Biological Technology Business Overview
  100. 7.17.3 Boster Biological Technology CD45 Antibody Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Boster Biological Technology CD45 Antibody Product Portfolio
  102. 7.17.5 Boster Biological Technology Recent Developments
  103. 7.18 Merck
  104. 7.18.1 Merck Company Information
  105. 7.18.2 Merck Business Overview
  106. 7.18.3 Merck CD45 Antibody Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Merck CD45 Antibody Product Portfolio
  108. 7.18.5 Merck Recent Developments
  109. 7.19 Thermo Fisher Scientific
  110. 7.19.1 Thermo Fisher Scientific Company Information
  111. 7.19.2 Thermo Fisher Scientific Business Overview
  112. 7.19.3 Thermo Fisher Scientific CD45 Antibody Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Thermo Fisher Scientific CD45 Antibody Product Portfolio
  114. 7.19.5 Thermo Fisher Scientific Recent Developments
8 North America
  1. 8.1 North America CD45 Antibody Revenue (2021-2032)
  2. 8.2 North America CD45 Antibody Revenue by Type (2021-2032)
  3. 8.2.1 North America CD45 Antibody Revenue by Type (2021-2026)
  4. 8.2.2 North America CD45 Antibody Revenue by Type (2027-2032)
  5. 8.3 North America CD45 Antibody Revenue Share by Type (2021-2032)
  6. 8.4 North America CD45 Antibody Revenue by Application (2021-2032)
  7. 8.4.1 North America CD45 Antibody Revenue by Application (2021-2026)
  8. 8.4.2 North America CD45 Antibody Revenue by Application (2027-2032)
  9. 8.5 North America CD45 Antibody Revenue Share by Application (2021-2032)
  10. 8.6 North America CD45 Antibody Revenue by Country
  11. 8.6.1 North America CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CD45 Antibody Revenue by Country (2021-2026)
  13. 8.6.3 North America CD45 Antibody Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CD45 Antibody Revenue (2021-2032)
  2. 9.2 Europe CD45 Antibody Revenue by Type (2021-2032)
  3. 9.2.1 Europe CD45 Antibody Revenue by Type (2021-2026)
  4. 9.2.2 Europe CD45 Antibody Revenue by Type (2027-2032)
  5. 9.3 Europe CD45 Antibody Revenue Share by Type (2021-2032)
  6. 9.4 Europe CD45 Antibody Revenue by Application (2021-2032)
  7. 9.4.1 Europe CD45 Antibody Revenue by Application (2021-2026)
  8. 9.4.2 Europe CD45 Antibody Revenue by Application (2027-2032)
  9. 9.5 Europe CD45 Antibody Revenue Share by Application (2021-2032)
  10. 9.6 Europe CD45 Antibody Revenue by Country
  11. 9.6.1 Europe CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CD45 Antibody Revenue by Country (2021-2026)
  13. 9.6.3 Europe CD45 Antibody Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China CD45 Antibody Revenue (2021-2032)
  2. 10.2 China CD45 Antibody Revenue by Type (2021-2032)
  3. 10.2.1 China CD45 Antibody Revenue by Type (2021-2026)
  4. 10.2.2 China CD45 Antibody Revenue by Type (2027-2032)
  5. 10.3 China CD45 Antibody Revenue Share by Type (2021-2032)
  6. 10.4 China CD45 Antibody Revenue by Application (2021-2032)
  7. 10.4.1 China CD45 Antibody Revenue by Application (2021-2026)
  8. 10.4.2 China CD45 Antibody Revenue by Application (2027-2032)
  9. 10.5 China CD45 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CD45 Antibody Revenue (2021-2032)
  2. 11.2 Asia CD45 Antibody Revenue by Type (2021-2032)
  3. 11.2.1 Asia CD45 Antibody Revenue by Type (2021-2026)
  4. 11.2.2 Asia CD45 Antibody Revenue by Type (2027-2032)
  5. 11.3 Asia CD45 Antibody Revenue Share by Type (2021-2032)
  6. 11.4 Asia CD45 Antibody Revenue by Application (2021-2032)
  7. 11.4.1 Asia CD45 Antibody Revenue by Application (2021-2026)
  8. 11.4.2 Asia CD45 Antibody Revenue by Application (2027-2032)
  9. 11.5 Asia CD45 Antibody Revenue Share by Application (2021-2032)
  10. 11.6 Asia CD45 Antibody Revenue by Country
  11. 11.6.1 Asia CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CD45 Antibody Revenue by Country (2021-2026)
  13. 11.6.3 Asia CD45 Antibody Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CD45 Antibody Revenue (2021-2032)
  2. 12.2 SAMEA CD45 Antibody Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CD45 Antibody Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CD45 Antibody Revenue by Type (2027-2032)
  5. 12.3 SAMEA CD45 Antibody Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CD45 Antibody Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CD45 Antibody Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CD45 Antibody Revenue by Application (2027-2032)
  9. 12.5 SAMEA CD45 Antibody Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CD45 Antibody Revenue by Country
  11. 12.6.1 SAMEA CD45 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CD45 Antibody Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CD45 Antibody Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst